Health ❯ Healthcare ❯ Obesity

Weight Management

GLP-1 Drugs Medications GLP-1 Receptor Agonists Semaglutide Mounjaro Dietary Interventions Weight Loss Medications Medication Options Weight Loss Treatments Dietary Medications

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

European Commission approval would create the first oral GLP‑1 for adult weight management with pricing left to EU Member States.

Stories older than 24h

New Risk Score Predicts 10-Year Risk for 18 Obesity-Linked Diseases

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

UK Pharmacies Report Cloned Websites Pushing Fake Weight-Loss Jabs as Trade Body Urges Crackdown

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies